Welcome to our dedicated page for SNBP news (Ticker: SNBP), a resource for investors and traders seeking the latest updates and insights on SNBP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SNBP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SNBP's position in the market.
Panbela Therapeutics has completed patient enrollment for its Phase 1 trial evaluating SBP-101 combined with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma (PDA). A total of 50 patients enrolled, with 30 on a dose schedule set for a future randomized trial. Results are expected in the first half of 2021. SBP-101 has received FDA Fast Track and orphan drug designations, indicating its potential in addressing unmet medical needs in pancreatic cancer treatment.
Sun BioPharma, Inc. (Nasdaq: SNBP) reported significant progress for Q3 2020, including the appointment of a new CEO and the receipt of Fast Track designation for SBP-101. The company successfully uplisted to the Nasdaq Capital Market and closed a $10.5 million public offering, enhancing its financial stability. SBP-101 showed a 54% objective response rate in its Phase 1 trial, more than double that of the historical standard of care for metastatic pancreatic cancer. The company targets upcoming milestones, including completing SBP-101 enrollment and initiating a Phase 2 study in early 2021.
Sun BioPharma (Nasdaq:SNBP) announced its participation in the 11th Annual Craig-Hallum Alpha Select Conference on November 17, 2020. Management will engage in one-on-one meetings with registered investors. The company develops SBP-101, a polyamine analogue targeting pancreatic cancer, which has shown potential tumor growth inhibition without worsening chemotherapy-related side effects. Sun BioPharma is committed to addressing urgent medical needs in pancreatic cancer, collaborating with several prestigious institutions for clinical studies.
Sun BioPharma, Inc. (Nasdaq: SNBP) announced a conference call on November 12, 2020, at 4:30 PM ET to discuss its third-quarter results for the period ended September 30, 2020. The call will provide insights into the company's developmental progress on SBP-101, a therapeutic targeting pancreatic cancer with indications of tumor growth inhibition in clinical trials. SBP-101 has shown safety without exacerbating typical chemotherapy-related side effects. Investors can participate by dialing in or accessing the call online.
